Quarterly Results

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE2576.6085 (+3.41 %)
PREV CLOSE ( ) 2491.60
OPEN PRICE ( ) 2560.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 286
TODAY'S LOW / HIGH ( )2539.30 2584.05
52 WK LOW / HIGH ( )2437.75 3953.95
NSE2573.5554.8 (+2.18 %)
PREV CLOSE( ) 2518.75
OPEN PRICE ( ) 2569.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 2573.55 (7)
VOLUME 4545
TODAY'S LOW / HIGH( ) 2540.25 2585.70
52 WK LOW / HIGH ( )2445.7 3960
Quarters
Select year  
( in Million)
Particulars
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Audited / UnAudited
UnAudited
UnAudited
UnAudited
UnAudited
Net Sales
2005.27
1977.08
1754.02
2102.57
Total Expenditure
1858.6
1797.92
1597.72
1698.48
PBIDT (Excl OI)
146.67
179.16
156.3
404.09
Other Income
53.31
28.43
28.99
25.53
Operating Profit
199.98
207.59
185.3
429.62
Interest
2.27
2.47
2.66
2.82
Exceptional Items
NA
NA
NA
NA
PBDT
197.71
205.12
182.64
426.8
Depreciation
35.06
42.76
47.61
58.42
Profit Before Tax
162.65
162.36
135.03
368.38
Tax
48.45
42.9
32.61
95.6
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
114.2
119.46
102.42
272.78
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
0.00
0.00
0.00
0.00
Net Profit
114.2
119.46
102.42
272.78
Equity Capital
50
50
50
50
Face Value (IN RS)
2
2
2
2
Reserves
Calculated EPS
4.56
4.77
4.09
10.91
Calculated EPS (Annualised)
18.27
19.11
16.38
43.64
No of Public Share Holdings
6250000
6250000
6250000
6250000
% of Public Share Holdings
25
25
25
25
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
7.31
9.06
8.91
19.21
PBIDTM%
9.97
10.49
10.56
20.43
PBDTM%
9.85
10.37
10.41
20.29
PBTM%
8.11
8.21
7.69
17.52
PATM%
5.69
6.04
5.83
12.97
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)